Radiofrequency ablation of haemodynamically unstable ventricular tachycardia after myocardial infarction

OBJECTIVE—To determine whether radiofrequency (RF) ablation might have a role in haemodynamically unstable ventricular tachycardia.
METHODS—10 patients with a history of ventricular tachycardia producing haemodynamic collapse in whom drug treatment had failed and device therapy was rejected underwent RF ablation of ventricular tachycardia in sinus rhythm. The arrhythmogenic zone was defined on the basis of abnormal systolic movement, the presence of fragmentation (low amplitude, prolonged multiphasic electrograms), and pace mapping. RF lesions were delivered in power mode in linear fashion within the defined arrhythmogenic zone.
RESULTS—Success (no ventricular tachycardia inducible postablation or at retest) was achieved in six patients, possible success (a different ventricular tachycardia inducible at more aggressive stimulation) in three. In one patient, the procedure was abandoned because of poor catheter stability. There were no clinical events during a mean (SD) follow up period of 23 (10) months in any of the nine patients defined as definite or possible successes.
CONCLUSIONS—RF ablation for addressing haemodynamically unstable ventricular tachycardia opens the door for the wider use of catheter ablation for treating this arrhythmia.


Keywords: tachycardia; catheter ablation; sudden death     

Catheter ablation for hemodynamically unstable monomorphic ventricular tachycardia

INTRODUCTION: Hemodynamic collapse precludes extensive catheter mapping to identify focal target regions in many patients with ventricular tachycardia (VT) associated with heart disease. This study tested the feasibility of catheter ablation of poorly tolerated VTs by targeting a region identified during sinus rhythm. METHODS AND RESULTS: Ablation was attempted in five patients, ages 44 to 59 years, with left ventricular ejection fractions of 0.15 to 0.20 and poorly tolerated VT causing multiple implantable defibrillator therapies (6 to 30 episodes/month). VT was due to prior infarction in three patients and nonischemic cardiomyopathy in two. Target regions were sought that met the following criteria: (1) evidence of slow conduction from fractionated sinus rhythm electrograms and stimulus-QRS delays during pace mapping, and (2) evidence that the region contains the reentrant circuit exit from pace mapping. In 4 of 5 patients, a target region was identified and radiofrequency lesions applied. Ablation abolished all recurrences of VT in 3 of 4 patients during follow-up of 14 to 22 months. There were no complications. CONCLUSION: Ablation of poorly tolerated VT is feasible in some patients by mapping during sinus rhythm and performing ablation over a region of identifiable scar that contains abnormal conduction and a presumptive VT exit.     

Catheter ablation of ventricular tachycardia

Opinion statement Most patients with ventricular tachycardia (VT) associated with structural heart disease should receive an implantable cardioverter-defibrillator as initial therapy. Patients with symptomatic recurrences of tachycardia, including those with multiple defibrillator shocks, are considered for ablation. The vigor with which antiarrhythmic drug therapy is pursued as antecedent therapy to ablation depends on patient factors (eg, medical comorbidity, type of heart disease, number and hemodynamic tolerance of tachycardias) and the previous history of antiarrhythmic drug exposure (eg, side effects, inefficacy). In patients with mild left ventricular dysfunction and well-tolerated tachycardia, ablation may be offered as primary definitive therapy in selected individuals. In patients without structural heart disease, ablation is usually offered as primary definitive therapy to highly symptomatic patients, and is strongly recommended for patients with recurrent tachycardia following initial attempts at drug suppression. Optimal outcome of VT ablation depends on the availability of an experienced team and sophisticated facilities to accommodate the technical challenges associated with the broad spectrum of clinical presentations and arrhythmia mechanisms. Historically, major complications have been reported in up to 10% of patients, including death, stroke, cardiac tamponade, complete heart block, and myocardial infarction. In our own experience with VT ablation over the past 10 years, major complications occurred in three (1.8%) of 168 patients with structural heart disease and one (0.7%) of 142 patients without structural heart disease.     

Catheter ablation for ventricular tachycardia

Sudden cardiac death due to ventricular arrhythmias remains the most common cause of death in developed nations. Implantable cardioverter defibrillators have been shown to improve mortality in high‐risk groups for ventricular tachyarrhythmias, but they are not curative, with the risk of arrhythmia recurrence remaining unaltered. It is also important to remember that ventricular tachycardia (VT) in the setting of a structurally normal heart is often not associated with an increased risk of sudden death and catheter ablation is a potentially curative procedure in this cohort. Recent advances in catheter ablation for VT have increased the efficacy in creating adequate lesions, accurate three‐dimensional maps and mapping haemodynamically unstable VT, all of which have increased the utility of this modality in the treatment of ventricular arrhythmias. In this article, we review the recent advances that have fuelled renewed interest in catheter ablation of VT, its clinical utility and who should be referred.     

Catheter ablation in ventricular tachycardia

The basis for management of ventricular tachycardia (VT) is pharmacologic treatment which is effective, however, in only about 20 to 30% of the patients. With respect to this problem, alternative therapeutic modes have been developed which include, in addition to antitachycardia stimulation, electrical, palliative therapy such as the implantable automatic defibrillator, definitive measures such as map-guided antitachycardia surgery and catheter ablation. The goal of catheter ablation is the selective destruction of heart structures which are the morphologic correlate for initiation of propagation of VT. Catheter ablation was discovered by chance by Fontaine after a defibrillation during an electrophysiologic study in which a defibrillating electrode in the proximity of a catheter at the His bundle induced complete AV-block. This effect of destruction in the AV-conduction system by direct current as a therapeutic measure was further developed by Gallagher and Scheinman. The mechanism held responsible is coagulation by the electrode of neighboring tissue and barotrauma. The technique, which was initially used for ablation of the His bundle in supraventricular tachycardia, can also be used for ablation of accessory pathways or the site of origin of VT which generally lies endocardially in marginal regions of myocardial infarctions. CATHETER MAPPING: In sinus rhythm and induced VT, endocavity catheter mapping is carried out after heparinization with electrocardiograms recorded from at least six to ten sites in the right and left ventricles. At the site of early activation, detailed mapping is used for identification of the site of earliest activation, then pace-mapping is performed during sinus rhythm and VT. The morphology of the stimulated QRS complexes is compared with that of the spontaneous VT. In patients in whom VT cannot be induced, localization is carried out by pace-mapping alone. CATHETER ABLATION: After localization, in intubation narcosis and with continuously monitored arterial blood pressure, the suspected site of origin of the VT is subjected to an initial shock during sinus rhythm by means of a distal electrode of a catheter in stable contact with the endocardium. For mapping and ablation, the same catheter is used. After each subsequent shock, assessment is performed to determine if the distal electrode pair still conducts local ventricular signals and if ventricular stimulation is possible. The shock energy delivered is 100, 200 or 400 Joules. At the time of shock discharge, the remaining electrodes or catheters are disconnected. In the case of bradycardia or tachycardia after the shock, immediate connection to an external stimulation generator is established. At the time of the shocks, relaxation is provided by succinylcholine. All shocks are delivered from the anode. The integrity of the catheter is tested after each shock, no catheter is used more than three or four times. At the earliest, ten minutes after shock delivery, induction of clinical VT is attempted with programmed stimulation and if induction is possible, at the same site a maximum of two more shocks are delivered or, after renewed mapping, another shock is delivered to a different site. Induced non-clinical VT is not subjected to ablation.(ABSTRACT TRUNCATED AT 400 WORDS)     

Catheter ablation of ventricular tachycardia]

Catheter ablation of ventricular tachycardias was performed in a total of 80 patients whose tachycardias were considered as drug refractory and who were not considered to be candidates for antitachycardic surgery or implantation of an automatic cardioverter defibrillator. After careful endocardial catheter mapping including pacing interventions, either direct-current (DC) (n = 61) or radiofrequency current (RF) (n = 13) or both (n = 6) were applied of the "site of origin" of ventricular tachycardia or the "zone of slow conduction". 42 of 51 patients with coronary heart disease were discharged; ventricular tachycardia recurred in 8 cases, and 2 patients died suddenly. In the remaining 32 patients, there were no recurrences of ventricular tachycardia during a mean follow-up period of 12 month. Three patients died perioperatively. In 21 of 29 patients without coronary artery disease, no recurrences of ventricular tachycardia were observed (mean duration of follow-up 17 months) whereas 8 cases had a recurrence of ventricular tachycardia.     

Catheter ablation of monomorphic ventricular tachycardia

PURPOSE OF REVIEW: Patients with ventricular tachycardia are subject to frequent recurrences and antiarrhythmic drug therapy has been disappointing. Catheter ablation offers an alternative means of controlling ventricular tachycardia. RECENT FINDINGS: The origin and pathophysiology of ventricular tachycardia are being defined for newly recognized types of ventricular tachycardia as well as scar-related ventricular tachycardias. The approach to mapping and ablation of ventricular tachycardia depends on the nature of the arrhythmia substrate, which is largely determined by the underlying heart disease. Focal origin ventricular tachycardias often occur in patients without structural heart disease. The right ventricular and left ventricular outflow tracts are common locations. Ablation is usually successful unless the focus is epicardial in location or in close proximity to the ostia of a coronary artery. The reentry path for idiopathic left ventricular reentrant ventricular tachycardia is now defined. In patients with heart disease, most ventricular tachycardias are scar related, with areas of fibrous tissue forming the border for reentry paths. Substrate mapping defines areas of scar, abnormal conduction, and reentry circuit exits during sinus rhythm. Ablation of multiple ventricular tachycardias and unstable ventricular tachycardias performed largely during sinus rhythm is often possible. Ablation is usually adjunctive therapy to an ICD in these patients. Epicardial mapping and ablation are needed in some patients. SUMMARY: Ablation is a reasonable alternative to antiarrhythmic drug therapy for controlling frequent ventricular tachycardia episodes in many patients. Further technological advances can be anticipated.     

Presyncope caused by non-sustained ventricular tachycardia. Significance of RF ablation

We describe a case of a 55-year-old man with episodes of presyncope caused by non-sustained ventricular tachycardia (ns-VT). Symptoms of significant weakness started when he was 30-year-old. In the last 2 years there was a substantial increase in frequency of presyncope from 2 per month to 8 per week. He does not have palpitations. Standard ECG, echocardiography and coronary angiography were normal. During an exercise test ns-VT 220/min (5 s, 20 x QRS) with LBBB morphology was documented. Successful RF ablation of ns-VT using the CARTO system was performed. During 4-month follow-up the patient remains free from ventricular arrhythmia.     

Adenosine-induced non-sustained polymorphic ventricular tachycardia

Adenosine has become widely used because of its diagnostic andtherapeutic value in the emergency management of arrhythimias.it produces transient heart block by slowing conduction throughtile AV node and thus terminates supraventricular tachycardiasthat involve the atrioventricular node. Bradyarrhythmias ofshort duration are common side effects of the use of this drug.Premature atrial and ventricular beats have also been reported.The very short half-life and lack of serious adverse effectsgenerally lead to the consideration that adenosine is a safedrug. We describe a 56-year-old woman with a supra ventriculartachycardia. To terminate this rhythm disorder intravenous adenosinewas given. Interruption of tile supra ventricular tachycardiawas followed by non-sustained polymorphic ventricular tachycardia.     

Catheter ablation of ventricular tachycardia in chagasic cardiomyopathy

There is a limited experience with catheter ablation for treatment of ventricular tachycardia (VT) in Chagasic cardiomyopathy. A 30-year-old woman experienced episodes of palpitations and syncope due to attacks of VT. A diagnosis of Chagas disease was established on a biological basis. Two-dimensional echo and contrast ventriculography showed an apical aneurysm with thrombus. Surgery was indicated to resect the aneurysm and ablate the VT. Ventricular tachycardia recurred 1 month later despite therapy, including amiodarone. Two clinical frequent and well-tolerated tachycardias were identified. The site of origin was located in the right ventricular apex and in the apical-lateral wall of the left ventricle, respectively. Catheter ablation was performed at two sites with DC shocks (total energy 600 J) after unsuccessful radiofrequency ablation. Holter recordings performed during the postoperative period showed only infrequent extrasystoles. After follow-up of 24 months the patient remains asymptomatic. Drug-refractory VT in Chagasic cardiomyopathy can be ablated by medium-energy DC shocks after failure of radiofrequency ablation.     

Catheter ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia

Arrhythmogenic right ventricular dysplasia (ARVD) is a progressive, genetically determined fibro-fatty infiltrative myocardial disease with an estimated prevalence in the general population to be 1:5,000 to 1:10,000. ARVD leads to electrical instability that may predispose to life-threatening ventricular arrhythmia, heart failure, and sudden death. We reviewed the pathological substrate for ventricular arrhythmias, ECG findings and treatment modalities in ARVD. Importantly, novel techniques such as electroanatomic and voltage mapping has greatly improved the identification of the scared substrate in the settings of ARVD and have improved safety and efficacy of VT ablation procedures associated with this entity.     

Catheter ablation of ventricular tachycardia using radiofrequency current.

Catheter ablation techniques have evolved as an alternative to map-guided surgery and proven effective in a variety of supraventricular tachyarrhythmias. Direct current catheter ablation has been shown to be effective in about 50 to 70% of cases. Approximately, 60% of patients with structural heart disease and monomorphic ventricular tachycardia were successfully treated using direct current ablation techniques. This overall success rate and possible risks associated with the use of direct current have stimulated the search for other energy sources appropriate for catheter ablation. Presently, only a few preliminary reports on the clinical efficacy of radiofrequency energy for the treatment of ventricular tachyarrhythmias in man exist. 23 patients with identifiable heart disease at a mean age of 52 +/- 17 years underwent radiofrequency catheter ablation. 16 patients had coronary artery disease, one patient dilative cardiomyopathy and six patients had arrhythmogenic right ventricular disease. All patients presented with chronic current sustained ventricular tachycardia. After detailed endocardial catheter mapping radiofrequency energy was applied at the site of earliest ventricular activation during ventricular tachycardia which could be entrained during fixed rate ventricular pacing at the site of origin of ventricular tachycardia. At all ablation sites a long latency between the stimulus and QRS complex was noted. Of 23 patients 18 were treated with radiofrequency alone whereas in five patients a second ablation procedure using direct current was performed. Following the ablation procedures, 14 patients (61%) remained free of ventricular tachycardia. One patient died due to congestive heart failure 21 months following ablation.(ABSTRACT TRUNCATED AT 250 WORDS)     

非接触球囊标测指导血流动力学不稳定性或非持续性室性心动过速的射频消融

目的探讨非接触球囊标测在指导血流动力学不稳定性或非持续性室性心动过速(室速)射频消融中的作用。方法17例室速患者,年龄50岁±9岁,经心室刺激诱发血流动力学不稳定性或非持续性室速后,使用非接触标测系统ENSITE3000标测室速的出口和(或)慢传导区,然后使用温控大头导管在室速出口作环形消融或横跨慢传导区进行线性消融。结果17例患者共诱发18次室速,周长为336MS±58MS。15例患者可确定室速的出口,为QRS波前10MS±16MS;其中5例是心肌梗死后室速,9例为右室流出道室速。5例心肌梗死后室速均可确定舒张期慢传导区,最早的心内膜舒张期电活动在QRS波前60·1MS±42·6MS。3例非持续性室速均可确定最早的心室激动点。18次室速中15次消融成功,1例没有进行消融,2例消融失败。结论非接触球囊心内膜标测能成功指导血流动力学不稳定性或非持续性室速的射频消融。     

Catheter ablation and antiarrhythmic drugs for haemodynamically tolerated post-infarction ventricular tachycardia; long-term outcome in relation to acute electrophysiological findings.

AIMS: Radiofrequency catheter ablation is effective at terminating ventricular tachycardia, but the overall clinical role of the technique in patients with a prior myocardial infarction is still debated, due to the uncertainties of the long-term reliability of the procedure. The purpose of this study was to prospectively investigate the relationship between acute results obtained by catheter ablation and long-term outcome in a homogeneous population of patients with post-myocardial infarction ventricular tachycardia. METHODS AND RESULTS: One hundred and twenty-four consecutive patients with recurrent, drug-refractory, haemodynamically tolerated ventricular tachycardia were included in the study. This population accounted for 30% of the patients with post-myocardial infarction ventricular tachycardia admitted between April 1992 and September 1997 to the investigating centres. The ablation was successful in eliminating sustained ventricular tachycardia in 91 of them (73%); a partial result was obtained in 21 (17%) and failure in 12 (10%). Low dose amiodarone and/or beta-blockers were maintained in 86% of the patients. Over a median follow-up of 41.5 months (interquartile range 30.5-59.5 months), there were 15 deaths (12%), three of which were sudden (2.4%); the 12 remaining patients died of heart failure. Event-free survival analysis showed a significantly lower ventricular tachycardia recurrence rate in patients with a successful procedure as compared to those with failure or a partial result (19% vs 53% at one year and 27% vs 60% at 3 years, P=0.003). A repeat procedure was performed in 15 patients with early recurrences and was followed in all by long-term success. Of those who submitted to a second procedure, 93/124 patients (75%) are free of ventricular tachycardia recurrences. An implantable cardioverter-defibrillator (ICD), following procedure failure, was implanted in 13 patients (11%) of the study population. CONCLUSIONS: Radiofrequency catheter ablation is effective in a wide population of patients with recurrent tolerated ventricular tachycardia, with very low sudden death and cardiac mortality rates over the long-term. Persistent ventricular tachycardia inducibility after catheter ablation requires an ICD implant and/or repeat ablation.